Leishmania (genus of parasitic protozoans)

Leishmania parasites are single-celled eukaryotic protozoans of the genus Leishmania, belonging to the class Kinetoplastea and are responsible for leishmaniasis, a serious infectious disease affecting humans worldwide[1][8]. These parasites infect host macrophages, survive within hostile intracellular environments by evading immune responses, and utilize unique metabolic pathways distinct from their mammalian hosts. Drug development against Leishmania focuses on specific molecules within the parasite, such as key enzymes, surface glycoproteins, kinases, and transporters. Increasing resistance to existing therapies and the absence of effective vaccines highlight the need for identification and validation of new molecular targets[2][3][9]. The term "Leishmania parasites" is too broad to serve as a canonical drug target; further specification at the molecular level (e.g., Leishmania 6-phosphogluconate dehydrogenase) is necessary for structured data extraction and focused therapeutic design.

Other names

Leishmania spp.Leishmania protozoaKinetoplastid parasites

Directly killing or inhibiting parasite growth by interfering with: Parasite metabolism (glycolysis inhibition); Disruption of membrane integrity (by amphotericin B, miltefosine); Inhibition of enzyme activity (e.g., IPC synthase, topoisomerases, kinases); Immune-mediated clearance (some antimonials influence host immune response).